乳酸司氟沙星注射液治疗细菌性感染62例  

Intravenous sparfloxacin lactate in treatment of 62 patients with bacterial infections

作　　者：贾蓓[1] 黄文祥[1] 王其南[1] 肖永红[1] 郑行萍[1] 刘鸿渝[1] 

机构地区：[1]重庆医科大学附属第一医院传染科,重庆400016

出　　处：《中国新药杂志》2003年第1期59-61,共3页Chinese Journal of New Drugs

摘　　要：目的 :评价司氟沙星注射液治疗细菌性感染的疗效和安全性。方法 :采用随机对照开放试验 ,试验组及开放组 62例 ,用司氟沙星 2 0 0～ 30 0mg ,qd ,对照组 32例用氧氟沙星 2 0 0mg ,bid或tid ,疗程 7～ 1 4d。 结果 :司氟沙星临床有效率、细菌清除率、细菌敏感率和不良反应发生率分别为 87.0 % ,88.2 % ,93 .9%和 1 6 .1 % ;氧氟沙星为78.1 % ,83 .8% ,91 .4%和 1 2 .5 %。 2组疗效和安全性结果经统计学处理均无显著性差异 (P >0 .0 5)。结论 :司氟沙星抗菌谱广 ,抗菌活性强 。Objective:To evaluate the clinical efficacy and safety of intravenous sparfloxacin (SPLX) administration.Methods:A randomized open trial was conducted in 94 patients.They were divided into the test group( n =32),the control group( n =32) and the open group( n =32) to receive introvenously SPLX injection 200～300 mg,qd,Ofloxacin(OFLX) injection 200mg,bid or tid,SPLX injection 200～300mg,qd,respectively for 7～14 days.Results:In the SPLX group, 87.0% of patients were clinically cured or improved compared with 78.1% of the patients in the OFLX group ( P > 0.05). The eradication rates of pathogens were 88.2% and 83.8%, respectively( P >0.05).The sensitivity rates of pathogens were 93.9% and 91.4%, respectively( P >0.05).And the rates of side effects were 16.1% and 12.5%, respectively( P >0.05).Conclusion:SPLX is a long acting,broad spectrum and effective agent for the treatment of acute and serious infectious diseases caused by sensitive pathogens.

关 键 词：司氟沙星 氧氟沙星 细菌性感染 

分 类 号：R978.11[医药卫生—药品]